Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

Abstract

Glaucoma is a degenerative, chronic ocular disease that causes irreversible vision loss. The major symptom of glaucoma is high intraocular pressure, which happens when the flow of aqueous humor between the front and back of the eye is blocked. Glaucoma therapy is challenging because of the low bioavailability of drugs from conventional ocular drug delivery systems such as eye drops, ointments, and gels. The low bioavailability of antiglaucoma agents could be due to the precorneal and corneal barriers as well as the low biopharmaceutical attributes of the drugs. These limitations can be overcome by employing nanoparticulate drug delivery systems. Over the last decade, there has been a lot of interest in chitosan-based nanoparticulate systems to overcome the limitations (such as poor residence time, low corneal permeability, etc.) associated with conventional ocular pharmaceutical products. Therefore, the main aim of the present manuscript is to review the recent research work involving the chitosan-based nanoparticulate system to treat glaucoma. It discusses the significance of the chitosan-based nanoparticulate system, which provides mucoadhesion to improve the residence time of drugs and their ocular bioavailability. Furthermore, different types of chitosan-based nanoparticulate systems are also discussed, namely nanoparticles of chitosan core only, nanoparticles coated with chitosan, and hybrid nanoparticles of chitosan. The manuscript also provides a critical analysis of contemporary research related to the impact of this chitosan-based nanomedicine on the corneal permeability, ocular bioavailability, and therapeutic performance of loaded antiglaucoma agents.

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems

“…Studies highlight the effectiveness of chitosan nanoparticles in enhancing drug delivery to the eye, addressing challenges such as low bioavailability and limited drug retention times associated with conventional drug delivery systems. Various studies have indicated that chitosan nanoparticles can improve the delivery and efficacy of antiglaucoma agents by overcoming barriers such as poor residence time and low corneal permeability, which are common limitations of traditional ocular pharmaceutical products [ 148 ]. Additionally, the mucoadhesive properties of chitosan also contribute to its potential applications, aiding in sustained drug release and enhanced therapeutic performance for glaucoma management [ 149 ].…”

Current Innovations in Intraocular Pressure Monitoring Biosensors for Diagnosis and Treatment of Glaucoma—Novel Strategies and Future Perspectives

“…Hence, glaucoma diagnosis and monitoring are very essential, and can be achieved by measuring the IOP [ 49 ]. In affected individuals, both retinal ganglion cells and retinal axons become damaged due to high levels of IOP and oxidative stress [ 50 ].…”

Advancements in Nanogels for Enhanced Ocular Drug Delivery: Cutting-Edge Strategies to Overcome Eye Barriers

“…Chitosan, a cationic hydrogel polymer, is widely used among these polymers. This is due to the fact that chitosan has great biocompatibility and includes an amino group that may be readily protonated [ 88 ]. Recently, Nguyen et al prepared pilocarpine-loaded ceria nanogel (Ce NC) coated with chitosan hydrogels for ocular application [ 89 ].…”